pharmaceutical investing Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy
Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Final Assay Results Confirm High-Grade, Near-Surface Fluorspar and Gallium Mineralisation at Monte Muambe
